ELCC 2019 | Treatment sequecing strategies in advanced NSCLC

Martin Reck

Martin Reck, MD, PhD, from Lung Clinic Grosshansdorf, Grosshansdorf, Germany, explains recent changes and sequencing strategies in non-mutated, non-squamous advanced non-small cell lung cancer (NSCLC). This interview took place at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland.

Share this video  
Similar topics
Related videos
0:48
The LUNAR study: TTFields for NSCLC
Ori Farber
0:55
Tumor treating fields as an anti-mitotic therapy
Ori Farber
0:48
Patient impact: development of drugs to treat METex14 alterations
Paul Paik
1:04
Tepotinib: advanced non-small cell lung cancer
Paul Paik
0:53
Future treatment options for squamous cell lung cancer
Paul Paik
Lung Cancer, Non-Small Cell Lung Cancer
Nintedanib, Ramucirumab
ELCC 2019
Interview
More from Martin Reck
Pembro continues to demonstrate OS benefit in first-line NSCLC: KEYNOTE-024 update
NSCLC: a treatment landscape in flux in the checkpoint inhibitor era
The LUME BioNIS trial: an exploratory study into lung cancer biomarkers
vjoncology logo VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals